Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200
NCT00455910
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
112
Enrollment
OTHER
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Thalidomide
Sponsor
Groupe Francophone des Myelodysplasies